The U.S. Food and Drug Administration approval in Sep 2018 of the drug Seizalam® (midazolam injection) as an anti-seizure medication, provided the nation with a medical countermeasure (MCM) for people exposed to [Read more]
The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium and the Critical Path Institute (C-Path) Predictive Safety Testing Consortium (PSTC) have received the first ever qualification of a clinical safety [Read more]
SIGA Technologies, Inc. today announced that it has entered into a Cooperative Research and Development Agreement (CRADA) with the United States Army Medical Research Institute of Infectious Diseases (USAMRIID). This CRADA will [Read more]
Melioidosis, also called Whitmore’s disease, is an infectious disease that can infect humans or animals. The disease is caused by the bacterium Burkholderia pseudomallei. Melioidosis: The Most Neglected Tropical Disease Why is Burkholderia [Read more]
The National Institutes of Health (NIH) has selected Soligenix’s SGX942 (dusquetide) for the treatment of oral mucositis in head and neck cancer (HNC) patients as a Small Business Innovation Research/Small Business Technology [Read more]
In a new article published in The Lancet, experts review the current field of Ebola vaccine candidates and clinical trials and highlight key gaps in knowledge that need to be addressed by [Read more]
Vaccinations have begun in a first-in-human trial of an experimental Zika virus vaccine, the National Institute of Allergy and Infectious Diseases (NIAID) announced today. The experimental vaccine, known as rZIKV/D4Δ30-713, was developed [Read more]
The Centers for Disease Control and Prevention (CDC) intends to award a sole source firm fixed price contract to Emergent Biodefense Operations Lansing LLC. The Government intends to purchase 9 Million doses [Read more]
Spero Therapeutics, Inc. today announced that it was awarded funding of $15.7 million, with the potential for up to an additional $28.5 million over 5 years, from the Biomedical Advanced Research and Development Authority (BARDA). The funding [Read more]
Soligenix, Inc. announced on July 9 that it has received notice of allowance for European and Canadian patent applications further extending protection around ThermoVax® including coverage of the Company’s ricin toxin vaccine, [Read more]
© 2019 STEMAR MEDIA